Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effects of the Anti-inflammatory Drug, Tofacitinib on Emotional and Reward Processing in Patients With Treatment-resistant Depression and Elevated High-sensitivity C-reactive Protein

Next Previous
Trial Profile

The Effects of the Anti-inflammatory Drug, Tofacitinib on Emotional and Reward Processing in Patients With Treatment-resistant Depression and Elevated High-sensitivity C-reactive Protein

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 12 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Major depressive disorder
  • Focus Pharmacodynamics
  • Acronyms TIDE

Most Recent Events

  • 08 Aug 2022 Status changed from suspended to discontinued.
  • 02 Nov 2020 Status changed from recruiting to suspended due to Covid-19 pandemic.
  • 13 Nov 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Oct 2019 to 1 Nov 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top